KRAS and metastatic colorectal cancer: The combination was approved in early 2025 for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) who have received prior chemotherapy.138 This dual-targeted approach addresses the feedback activation of EGFR signaling that often limits the efficacy of KRAS inhibitors alone.